BTIG Reiterates Buy Rating on Sensei Biotherapeutics, Inc.
BTIG maintains its Buy rating on Sensei Biotherapeutics with a $55 price target, a 297.11% upside from the current price.
Key Points
- BTIG analyst Jeet Mukherjee reiterated a Buy rating on Sensei Biotherapeutics, Inc. (SNSE) on June 11, 2026, with a $55 price target.
- BTIG's $55 price target implies 297.11% upside from Sensei Biotherapeutics, Inc.'s ($SNSE) current $13.85 share price.
- Shares of Sensei Biotherapeutics traded near $13 with a market cap of about $17.45 million, and a 52-week range of $5.86 to $36.76.
- Multiple insiders, including President Christopher Gerry, purchased shares on June 10, 2026, while BTIG and other firms maintain positive analyst ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BTIG analyst Jeet Mukherjee has reiterated a Buy rating on Sensei Biotherapeutics, Inc. (NASDAQCM:SNSE) as of June 11, 2026. The firm set a price target of $55, indicating confidence in the company's future prospects. Shares of Sensei Biotherapeutics are currently trading around $13.
Analysts Set New Price Targets
On June 11, 2026, BTIG reiterated its Buy rating for Sensei Biotherapeutics with a $55 price target. Lucid Capital Markets also initiated coverage with a Buy rating and a $50 target on May 28, 2026. Citigroup followed suit on May 22, 2026, with a Buy rating and a $55 target. These ratings suggest that analysts are optimistic about the company's potential growth.
Sensei Biotherapeutics Stock Snapshot
Shares of Sensei Biotherapeutics traded near $13 on the Nasdaq Capital Market. The company has a market cap of approximately $17.45 million. With a 52-week low of $5.86 and a high of $36.76, the stock has shown significant volatility. Its 50-day moving average is $23.38, while the 200-day moving average stands at $16.26. The company has a robust current ratio of 14.39, indicating strong liquidity.
Insider Buying and Selling at Sensei Biotherapeutics, Inc.
On June 10, 2026, several insiders, including President Christopher Gerry, bought shares of Sensei Biotherapeutics. Gerry purchased 220,000 shares. Bob Holmen and Phillip Donenberg each acquired 12,500 shares. On June 1, 2026, James Peyer and Cambrian Biopharma Inc. sold 25,000 shares each at an average price of $20.02.
About Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics, Inc. is a biotechnology company based in Rockville, Maryland. It focuses on developing therapeutics for cancer treatment. The company's pipeline includes PIKTOR, a multi-node inhibitor for endometrial and breast cancer, and Solnerstotug, a monoclonal antibody targeting solid tumors. Founded in 1999, the company was formerly known as Panacea Pharmaceuticals, Inc.
Bottom Line
BTIG's reiterated Buy rating and $55 price target reflect ongoing confidence in Sensei Biotherapeutics' potential. With shares trading around $13, the company is under close watch by investors and analysts alike. Insider buying further emphasizes the belief in the company's future, while analyst ratings suggest optimism about its growth trajectory.
Get Sensei Biotherapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SNSE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.